SCHEMBL584784

SCHEMBL584784

Clc1[c]nc2ccccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
GLA P06280 3/20 0.46
MAPT P10636 3/20 0.46
HPGD P15428 3/20 0.46
ACHE P22303 1/20 0.46
KMT2A Q03164 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
NQO2 P16083 1/20 0.39
KDM4E B2RXH2 4/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
CYP1A2 P05177 1/20 0.36
GAA P10253 2/20 0.35
HTR3A P46098 1/20 0.35
STAT3 P40763 1/20 0.35
LMNA P02545 2/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL269884 0.74 ALDH1A1 (0.46) ALDH1A1GLAMAPTHPGDACHE
SCHEMBL521935 0.74 NQO2 (0.46) ALDH1A1GLAMAPTHPGDACHE
SCHEMBL641339 0.74 ALDH1A1 (0.47) ALDH1A1GLAMAPTHPGDACHE
SCHEMBL558480 0.74 ALDH1A1 (0.46) ALDH1A1GLAMAPTHPGDACHE
SCHEMBL7060124 0.74 ALDH1A1 (0.46) ALDH1A1GLAMAPTHPGDACHE
SCHEMBL558535 0.74 ALDH1A1 (0.46) ALDH1A1GLAMAPTHPGDACHE
SCHEMBL628270 0.71 ALDH1A1 (0.43) ALDH1A1GLAMAPTHPGDACHE
SCHEMBL4723728 0.71 NCF1 (0.44) ALDH1A1GLAMAPTHPGDACHE
SCHEMBL328898 0.69 ALDH1A1 (0.44) ALDH1A1GLAMAPTHPGDACHE
SCHEMBL5250342 0.69 MAPT (0.41) ALDH1A1GLAMAPTHPGDACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10829466-B2 Stilbene derivative and preparation method thereof BEIJING INSTITUTE OF TECHNOLOGY (CN) 2020-11-10 US claimed
US-20200148662-A1 NOVEL STILBENE DERIVATIVE AND PREPARATION METHOD THEREOF BEIJING INSTITUTE OF TECHNOLOGY (CN) 2020-05-14 US claimed
US-20170174633-A1 PYRAZOLE COMPOUNDS SELECTIVE FOR NEUROTENSIN 2 RECEPTOR NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2017-06-22 US claimed
WO-2015148465-A1 PYRAZOLE COMPOUNDS SELECTIVE FOR NEUROTENSIN 2 RECEPTOR RESEARCH TRIANGLE INSTITUTE (US) 2015-10-01 WO claimed
US-9044478-B2 Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2015-06-02 US claimed
EP-1847545-B1 SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME UBE INDUSTRIES (JP) 2013-03-06 EP claimed
US-8137821-B2 Substituted ethynyl gold-nitrogen containing heterocyclic carbene complex and organic electroluminescent device using the same UBE INDUSTRIES, LTD. (JP) 2012-03-20 US claimed
EP-1809288-B1 USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES INST NAT SANTE RECH MED (FR) 2011-09-14 EP claimed
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US claimed
US-20090149464-A1 Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases UNIVERSITE DU DROIT ET DE LA SANTE- LILLE II (FR) 2009-06-11 US claimed
US-20090091243-A1 Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same UBE INDUSTRIES, LTD. (JP) 2009-04-09 US claimed
EP-2023728-A2 OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE Janssen Pharmaceutica, N.V. (BE) 2009-02-18 EP claimed
WO-2007140005-A2 OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-06 WO claimed
EP-1847545-A1 SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME Ube Industries, Ltd. (JP) 2007-10-24 EP claimed
EP-1809288-A1 USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2007-07-25 EP claimed
WO-2006051489-A1 USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2006-05-18 WO claimed
US-5270308-A Hypotensives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-12-14 US claimed
US-5021576-A Antiinflammatory, antiarthritic, hypotensive, anticarcinogenic agents AMERICAN HOME PRODUCTS CORPORATION (US) 1991-06-04 US claimed
CN-114105960-A Oxaadamantane derivatives capable of inhibiting activity of indoleamine 2, 3-dioxygenase 齐鲁制药有限公司 2022-03-01 CN disclosed
EP-0035228-A1 Tetrazole derivatives, process for the preparation thereof, and anti-ulcer composition containing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1981-09-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149464-A1 Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases PSEN1, PSEN2, SNCA ALDH1A1 129/4885GLA 2349/4885MAPT 22/4885
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase FAAH, FAAH2, APEH ALDH1A1 635/4885GLA 3621/4885MAPT 2537/4885
US-20170174633-A1 PYRAZOLE COMPOUNDS SELECTIVE FOR NEUROTENSIN 2 RECEPTOR NTSR2, NTSR1, NPFFR2 ALDH1A1 3651/4885GLA 4514/4885MAPT 1425/4885
US-10829466-B2 Stilbene derivative and preparation method thereof STS, F12, GLB1 ALDH1A1 449/4885GLA 711/4885MAPT 3955/4885
US-20200148662-A1 NOVEL STILBENE DERIVATIVE AND PREPARATION METHOD THEREOF STS, F12, STK38L ALDH1A1 415/4885GLA 838/4885MAPT 3976/4885
US-20090091243-A1 Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same ACSL3, ATXN2L, ACSL1 ALDH1A1 754/4885GLA 1794/4885MAPT 4507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.